Eton Pharmaceuticals Inc
21925 W Field Pkwy Ste 235
Phone: (847) 787-7361p:847 787-7361 DEER PARK, IL  60010-7208  United States Ticker: ETONETON

Eton Pharma files U.S. marketing application for topiramate oral solution

October 16 -- Eton Pharmaceuticals (NASDAQ:ETON) has submitted a marketing application to the FDA seeking approval of topiramate oral solution for three indications:

Monotherapy for partial-onset or primary general tonic-clonic seizures in patients at least two years old.

Adjunctive therapy for partial-onset seizures, including seizures associated with Lennox-Gastaut syndrome, in patients at least two years old.

Preventative treatment of migraine in patients at least 12 years old.

The company says its offering, if approved, will be the first and only liquid formulation of the antiepileptic med.

Shares up 2% after-hours.

Related Businesses
- - Customer

Copyright © 2020 by (Ticker: CRMZ®). All rights reserved.  You are not permitted to use this report or the information contained herein for any purpose not expressly permitted by, Inc. Except as expressly permitted by, Inc., you are not permitted, in whole or in part, to copy, alter, correct, adapt, translate, enhance, lease, sell, sublicense, assign, distribute, publish, otherwise make available to any third party, or prepare derivative works or improvements of this report or any of the information contained therein. You are not permitted to reverse engineer, disassemble, decompile, decode, or adapt the software, algorithms or other processes used to prepare this report, or otherwise attempt to derive or gain access to the source code of same. You agree not to remove, alter, obscure, combine or otherwise change any disclaimers, trademarks, copyrights, other intellectual property rights, proprietary rights, or other symbols, notices, marks, or serial numbers on or relating to any copy of the report or on marketing or other materials that, Inc. may provide to you. You will not use this report in any manner or for any purpose that infringes, misappropriates, or otherwise violates any right of any party, or that violates any applicable law.  
The FRISK® scores, agency ratings, credit limit recommendations and other scores, analysis and commentary are opinions of, Inc. and/or its suppliers, not statements of fact, and should be one of several factors in making credit decisions.  Any reliance you place on the information in this report is strictly at your own risk. Except as expressly provided by, Inc., no warranties or representations of any type, including without limitation of results to be obtained, merchantability or fitness for a particular purpose, are made concerning any part of, Inc.’s service, including without limitation the FRISK® scores.  The information published above has been obtained from sources CreditRiskMonitor considers to be reliable., Inc. and its third-party suppliers do not guarantee or validate the accuracy and completeness of the information provided in this report, the underlying information input to create the FRISK® scores, and specifically do not assume responsibility for not reporting any information omitted or withheld.  By using this website, you accept the Terms of Use Agreement
Contact Us: 845.230.3000
Fundamental financial data concerning public companies may be provided by Refinitiv (click for restrictions)
Tuesday, October 27, 2020